52% of doctors say that access to medical care has worsened after the outbreak of the coronavirus epidemic, because anything not related to COVID-19 now works on the residual principle, according to an online survey by the RNC Pharma analyst company and the Doktor Na Rabote (Doctor at Work) social media service for doctors. Another 40% believe that the situation is close to critical, because doctors are overloaded, and many healthcare facilities are being re-profiled, while the retired capacities are not compensated in any way. It is mostly the doctors from Moscow and St. Petersburg who consider the situation critical. This correlates with the morbidity statistics, at the time of the survey Moscow accounted for more than 50% of all COVID-19 cases.

It is unlikely that the Russian pharmaceutical market players that launched various anti-crisis programs a couple of years ago could have guessed that early 2020 would shock them with the coronavirus, rush demand and desperate regulatory activity. While they could feel a crisis approaching, they were still preparing for something else.

Between January and April 2020, the sales of veterinary drugs in the retail market amounted to 6.9 bln RUB (retail prices, VAT included), with the dynamics in monetary terms (rubles) of +0.6%. In comparison with the Q1 dynamics (+20.4%), the dynamics in April seem twice as modest. If calculated in minimum dosage units (MDU), the market volume is 65 bln MDUs, with the dynamics of +2.8%.

36% of doctors say that no COVID-19 testing is conducted in the hospitals where they work, according to an online survey by the RNC Pharma analyst company and the Doktor Na Rabote (Doctor at Work) social media service for doctors.

Between January and March 2020, Russia imported 262 thousand units of pharmaceutical drugs for clinical trials (CT), worth 6 bln RUB (customs clearance prices, VAT included). The dynamics in both monetary (rubles) and physical terms (units) are +56%. The number of imported trademarks has risen from 320 to 386. The number of placebo drugs has grown from 109 to 139 trademarks. In physical terms, placebos account for around 30% of the import (against 46% in 2019), while in monetary terms it is 21.7% (nearly the same as in 2019).

Only 7% of doctors think that the incidence of coronavirus infection in Russia will start declining as early as mid-May, according to an online survey by the RNC Pharma analyst company and the Doktor Na Rabote (Doctor at Work) social media service for doctors.

Only 8% of Russian doctors say that the healthcare facilities they work in provide all the necessary personal protective equipment, according to an online survey by the RNC Pharma analyst company and the Doktor Na Rabote (Doctor at Work) social media service for doctors. Another 17% say that there have been some interruptions in the provision, but the situation is not critical in general.

Between January and March 2020, Russia manufactured 102.6 bln RUB worth of pharmaceutical drugs (manufacturers’ prices, VAT included), which is in monetary terms (rubles) 18 higher than that of the same period in 2019. While the dynamics in monetary terms are promising and not much different from those in late 2019, the dynamics in physical terms (units) are only +0.2%, with 1 bln units manufactured. If calculated in minimum dosage units (MDU), the manufactures volume amounts to 18.6 bln MDUs, with the dynamics of +8.2%.

In Q1 2020, the sales of veterinary drugs in the retail market amounted to 4.88 bln RUB (retail prices, VAT included), with the dynamics of +20.4%. The high dynamics could be explained by a number of factors, in particular average price increase and increased demand. The latter could be attributed to atypical weather earlier this year, hence a shift in demand. If calculated in minimum dosage units (MDU), the market volume is 47.4 bln MDUs, with the dynamics of more than +10%.

Between January and March 2020, Russia imported 2.1 bln RUB worth of veterinary vaccines (customs clearance prices), which is in monetary terms (rubles) 8.4% lower than that of the same period in 2019. The dynamics in physical terms (units) are as low as -24.8%, or, if calculated in dosages, 13.5%. The import volume amounts to 1.13 mln units, or around 10.16 bln dosages.